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Abstract
Accurate HPV typing is essential for evaluation and monitoring of HPV vaccines, for second-line testing in cervical cancer screening, and in
epidemiological surveys. In this study, we set up and assessed in clinical samples a new HPV typing method based on 454 next-generation
sequencing (NGS) of HPV L1 amplicons, generated by using a modiﬁed PGMY primer set with improved sensitivity for some HPV types that
are not targeted by standard PGMY primers. By using a median 12 800-fold coverage, the NGS method allowed us to correctly identify all
high-risk HPV types, in either single or multiple infections, with a sensitivity of 50 genome equivalents, as demonstrated by testing WHO
LabNet EQA sample panels. Analysis of mixtures of HPV16- and HPV18-positive cell lines demonstrated that the NGS method could
reproducibly quantify the proportion of each HPV type in multiple infections in a wide dynamic range. Testing of HPV-positive clinical
samples showed that NGS could correctly identify a high number of HPV types in multiple infections. The NGS method was also effective in
the analysis of a set of cervical specimens with discordant results at hybrid capture 2 and line probe assays. In conclusion, a new HPV typing
method based on 454 pyrosequencing was set up. This method was sensitive, speciﬁc, quantitative and precise in both single and multiple
infections. It could identify a wide range of HPV types and might potentially discover new HPV types.
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Introduction
With the implementation of prophylactic HPV vaccination
programmes, accurate HPV typing methods are needed for the
evaluation of HPV vaccine efﬁcacy and for monitoring the
distribution of HPV types in the general population and in
vaccinated cohorts [1]. In addition, HPV typing has been
introduced in cervical cancer screening programmes as a
second line test for the management of women with high-risk
HPV infection and could be relevant in the follow-up of HPV-
positive (and cytology-negative) women in screening with HPV
as primary screening test [2,3]. As individual high-risk HPV
types differ in their oncogenic potential [4], identiﬁcation of
the presence of high-risk HPV types that are more strongly
associated with invasive cervical cancer (i.e. HPV16, HPV18
and HPV45) [5], may improve risk stratiﬁcation and manage-
ment of HPV-positive women.
The deﬁnition of the oncogenic potential of individual HPV
types is based mainly on the epidemiological evidence of the
association between HPV DNA detection and invasive cancer;
furthermore, for some rare HPV types phylogenetic similar-
ities have been considered for attributing the risk class [4,5].
Thus, the accuracy of HPV detection and typing is also
important because it might affect some of these evaluations. In
this regard, the WHO Global Proﬁciency Studies demon-
strated the need to improve methods for reliable HPV
genotyping, as many false-positive and false-negative results
were reported from participating laboratories [6,7]. A recent
large study on invasive cervical cancer addressed the impor-
tance of accurate broad-spectrum HPV detection and typing.
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In this study, out of 10 575 globally collected invasive cervical
carcinoma specimens, the presence of HPV DNA could be
detected in 84.9% of specimens and HPV types could be
identiﬁed in 96.3% of the positive cases [8]. In the same case
series, a further analysis of the HPV-positive invasive cancers
with unidentiﬁed HPV types, that used novel primer sets for
genotyping, demonstrated the presence of possibly carcino-
genic IARC group 2B HPV types and rare variants of
carcinogenic HPV types that have infrequently or never been
detected in invasive cervical cancer and that are usually not
targeted by currently used hybridization-based genotyping
assays [9].
We recently reported the proof of principle that next-
generation sequencing (NGS) may be used for HPV typing
[10]. Potential advantages of an NGS typing method compared
with hybridization-based assays are (i) the high speciﬁcity of a
sequencing-based method; (ii) the broad spectrum of detect-
able HPV types, including not yet discovered HPV types; (iii)
the ability to identify sequence subtypes, variants and muta-
tions; and (iv) the ability to identify different HPV types and to
estimate their relative amount in multiple infections. The NGS
HPV typing method we developed was based on 454
pyrosequencing of HPV L1 amplicons generated by PCR
ampliﬁcation with MY09/11 degenerate consensus primers
[10]. This method could identify HPV types in multiple
infections with relatively high sensitivity; however, the low
sensitivity of the MY09/11 primer set for some HPV types was
not increased by deep-sequencing [10]. In the present study,
we improved the HPV NGS typing protocol by designing a new
primer set based on modiﬁed PGMY multiplex primers and by
analysing longer reads generated by the 454 titanium chem-
istry. The analytical performance of the new protocol was
assessed in reference and clinical specimens and its analytical
accuracy was compared with hybridization-based assays. The
clinical diagnostic accuracy of the HPV NGS typing protocol
was not evaluated in this study.
Methods
Specimens
The following groups of samples were analysed in order to
evaluate distinct features of the 454 NGS-based HPV geno-
typing test. The different experiments that were performed,
with their design and objectives, are summarized in Table 1.
HPV-positive cell lines. To assess the reproducibility and
linearity of the NGS test, HPV16 and HPV18 DNA-positive
controls were prepared with DNA puriﬁed from CaSki and
HeLa cells (which contain c. 500 and 50 copies of HPV16 and
HPV18 genome per cell, respectively) and diluted in DNA T
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carrier obtained from the HPV-negative HEK293 cells,
according to the WHO Human Papillomavirus Laboratory
Manual [11]. CaSki and HeLa cell DNA was mixed in six
different proportions to generate multiple infection control
samples, corresponding to the following proportions of HPV16
to HPV18 genome equivalents (GE): 1000:1, 500:1, 100:1, 10:1,
1:1 and 1:5.
WHO proﬁciency panel specimens. To benchmark the ability
of genotyping multiple infections, HPV DNA of the 2010 and
2011 WHO proﬁciency study of HPV genotyping were used as
reference samples [6]. The panels were composed of puriﬁed
plasmid DNA in which genomic DNA of different HPV types
was cloned and diluted in a background of human placental
DNA as previously described [7,11]. Each panel was composed
of 43 reference samples that contained different amounts of
plasmids (5 and 50 IU per 5 lL for HPV16 and HPV18 and 50,
and 500 GE per 5 lL for the other high-risk HPV types 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66, 68a and 68b, and the low-risk
HPV types 6 and 11) and three reference samples that
contained HPV-positive and HPV-negative cell lines, as
described in the report of the WHO proﬁciency study [7].
Some samples contained different HPV types to mimic multiple
infections.
Pools of HPV-positive genital swabs. A group of 30 genital
swabs collected at Padova University Hospital from patients
with a positive result at the INNO-LiPA HPV Genotyping
Extra assay (Innogenetics, Gent, Belgium), which is based on
SPF10 primers (SPF10-LiPA), were analysed retrospectively to
assess the ability of the 454 pyrosequencing method to identify
HPV types in multiple infections. Samples were selected
consecutively among those with multiple infections and
representative of different HPV types. Nucleic acids puriﬁed
from these samples were pooled in equal amounts to generate
10 samples with a large number of different HPV types.
Cervical swabs with discordant hybrid capture and SPF10-LiPA
results. A group of eight consecutive cervical cytology speci-
mens with discordant results at hybrid capture 2 (HC2; Qiagen
Corporation, Gaithersburg, MD, USA) and SPF10-LiPA testing
were retrospectively selected for typing with the 454 pyrose-
quencing method. The HC2 assay and SPF10-LiPA were
carried out according to the manufacturer’s instructions.
Discordant samples were also tested with previously
described HPV type-speciﬁc real-time PCR assays targeting
HPV types 16, 18, 31, 33, 45, 52 and 58 [12,13].
Protocol for HPV typing by 454 pyrosequencing
Total DNA was puriﬁed from anogenital swab specimens by
using the MagNA Pure 96 Viral NA Small Volume Kit on a
MagNA Pure 96TM instrument (Roche Diagnostics, Monza,
Italy). To generate amplicons for the 454 NGS library, c. 100 ng
of puriﬁed DNA was ampliﬁed by PCR with fusion primers and
AmpliTaq Gold DNA Polymerase (Life Technologies Italia,
Monza, Italy). Multiplex fusion primers were designed in order
to contain the PGMY primer sequences reported in the WHO
Human Papillomavirus Laboratory Manual [11], the A e B
sequencing adapters (i.e. 5′-CGTATCGCCTCCCTCGCGCC
A-3′ and 5′-CTATGCGCCTTGCCAGCCCGC-3′, respec-
tively) and the key sequence (i.e. 5′-TCAG-3′) required for
454 NGS, and one of eight different 10 bp multiplex identiﬁer
(MID) barcodes, according to the manufacturer’s GS FLX
Standard sequencing method. As the PGMY primers set
recommended by the WHO manual cannot detect HPV68a,
we designed an additional primer pair speciﬁc for this high-risk
HPV type (i.e. PGMY09 5′-CGTCCTAATGGGAATTGGTC-3′
and PGMY11 5′-GCACAGGGACACAACAATGG-3′). PCR
conditions were one cycle of 95°C for 10 min, followed by 40
cycles at 95°C for 30 s, 55°C for 90 s and 72°C for 2 min, and a
ﬁnal 7-min step at 72°C. PCR products were puriﬁed by
AMPure beads (Agencourt Bioscience Corporation, Beverly,
MA, USA), quantiﬁed, diluted to 4 9 10^6 molecules/lL, and
pooled according to MID barcode compatibility. Each pool was
ampliﬁed by emulsion PCR (emPCR) using the GS-FLX emPCR
Kit II and III and sequenced at 50009 in both forward and
reverse directions coverage on a Genome Sequencer FLX
Instrument by using the GS FLX Titanium chemistry (Roche
454 Life Sciences, Branford, CT, USA). The average read length
obtained from NGS runs was 358.3  129.5 nucleotides, in
agreement with the median read size yielded by the GS FLX
Titanium protocol. The median number of reads per sample
was 12 806, range 3685–34990. Raw data will be submitted to
the SRA database.
Analysis of 454 pyrosequencing data
HPV typing was carried out by means of a custom analysis
pipeline, as described in [10]. A minimum cut-off of ﬁve reads
was used to deﬁne genotype detection. Reads that did not align
with known HPV genotypes were further analysed by means of
BLAST searches against the non-redundant database of
nucleotide sequences and were identiﬁed as human genomic
DNA contaminant. Analysis of 454 pyrosequencing data was
performed blind to the results of the other HPV detection and
genotyping tests.
Results
Sensitivity and speciﬁcity in WHO Panel 2010 and 2011
In a ﬁrst pyrosequencing run, a PGMY multiplex primer set,
which was designed based on the sequences recommended in
the WHO Laboratory manual [11], was used to analyse the
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WHO 2010 and 2011 proﬁciency panel samples. In all samples,
HPV types were correctly detected and typed at both 10 and
100 GE/lL concentrations, with the exception of HPV68a,
which was never detected. In samples with multiple HPV types,
the number of reads obtained for HPV31, HPV33, HPV51 and
HPV56 was c. ten-fold lower than other HPV types, suggesting
a different sensitivity of the method for these HPV types.
As the PGMY primers were shown to be unable to detect
HPV68a due to several mismatches also in the WHO
proﬁciency study [7], we designed a new primer pair targeting
HPV68a and added it to the PGMY primer mix. The sensitivity
and speciﬁcity of the modiﬁed PGMY primer set for HPV68a
was investigated with a new NGS run in eight samples of the
WHO 2010 proﬁciency panel containing HPV68a or HPV68b
as single or multiple infections and in ten samples negative for
HPV68a and HPV68b (Table 1). The results of the 454 NGS
run demonstrated that the modiﬁed PGMY primer mix
allowed 100% correct identiﬁcation of all genotypes in all
samples, including HPV68a at both 10 and 100 GE/lL, both in
single and in multiple infections (Table 2). The number of
HPV68a reads was higher than the reads of other genotypes in
multiple infections. This was probably due to the different
sensitivity of primers, because those targeting HPV68a had no
mismatches with their target, at variance with other target
HPV types (Table 2).
Reproducibility and quantitative analysis of HPV16- and
HPV18-positive samples
To analyse the reproducibility of the 454 pyrosequencing
method, nucleic acids puriﬁed from CaSki and HeLa cell lines
were mixed in different proportions, in order to obtain six
different percentages of HPV16 and HPV18 genome copies,
ranging from 0.1% to 80% of HPV16 genome equivalents of the
total number of HPV16 and HPV18 genome equivalents. The
samples were both ampliﬁed and sequenced in duplicate with
fusion primers tagged with MID1 and MID2. The results of this
test are shown in Fig. 1. Not only the percentage (Fig. 1b) but
also the absolute number of reads (Fig. 1a) of the two HPV
types obtained by 454 pyrosequencing was highly reproducible
and the percentage of reads correlated with the percentage of
each HPV type that was present in the sample mix (regression
analysis, R2 = 0.97).
Analysis of multiple HPV infections
Ten pools of samples with multiple HPV infection identiﬁed by
SPF10-LiPA were generated to assess the ability of the 454
pyrosequencing method to detect HPV types in multiple
infections. The results of this analysis are reported in Table 3.
In most cases, the 454 pyrosequencing method detected all
expected HPV types identiﬁed by SPF10-LiPA. In addition, in
some samples, the 454 pyrosequencing method detected HPV
types that are not targeted by the SPF-10 LiPA method (e.g.
HPV55 and HPV83). In some cases, 454 pyrosequencing did
not detect HPV types identiﬁed by SPF10-LiPA. These
discrepancies were mainly due to the different abilities of the
two methods to amplify particular HPV types [6,7]. In addition,
some discrepancies were associated with questionable geno-
typing results generated by the SPF10-LiPA due to the line-
probe interpretation algorithm of the assay, at variance with
the 454 pyrosequencing that generated unambiguous geno-
typing results.
Analysis of samples with discordant HC2 and SPF10-LiPA
results
Eight samples with discordant HC2 and SPF10-LiPA results
were analysed by 454 pyrosequencing (Table 4). Type-
speciﬁc real-time PCR was carried out to further investi-
gate discrepant ﬁndings. HPV detection and typing by 454
pyrosequencing appeared an accurate and sensitive method,
which could detect the presence of high-risk HPV infection
not detected by HC2 or the presence of some high-risk
HPV types, such as HPV59, for which the SPF10-LiPA
system has low sensitivity. The 454 pyrosequencing system
also indicated false-positive results by either HC2 (e.g.
HC2 positivity in the presence of low-risk or possibly high-
risk HPV types such as HPV53 and HPV66) or SPF10-LiPA
TABLE 2. Results of HPV genotyping of WHO 2010 proﬁ-
ciency panel samples by using a modiﬁed PGMY primer mix
and 454 pyrosequencing
HPV type
HPV
GE/ll
Primer
MID
454 pyrosequencing results
(No. reads)
HPV11 10 MID4 HPV11 (6498)
HPV11 100 MID6 HPV11 (5177)
HPV18 1 MID8 HPV18 (6208)
HPV18 10 MID7 HPV18 (9756)
HPV59 10 MID1 HPV59 (6754)
HPV59 100 MID8 HPV59 (12535)
HPV68a 10 MID2 HPV68a (7934)
HPV68a 100 MID3 HPV68a (6780)
HPV68b 10 MID6 HPV68b (8668)
HPV68b 100 MID5 HPV68b (8675)
HPV6, 16, 18, 51 10 MID8 HPV6b (950), HPV16 (825),
HPV18 (454), HPV51 (52)
HPV6, 16, 18, 51 100 MID6 HPV6b (1237), HPV16 (972),
HPV18 (740), HPV51 (67)
HPV11, 16, 31, 33, 58 10 MID7 HPV11 (3447), HPV16 (3326),
HPV31 (21), HPV33 (86),
HPV58 (1655)
HPV11, 16, 31, 33, 58 100 MID4 HPV11 (2876), HPV16 (3165),
HPV31 (144), HPV33 (236),
HPV58 (2054)
HPV39, 45, 52, 56, 68a 10 MID5 HPV39 (22), HPV45 (129),
HPV52 (391), HPV56 (58),
HPV68a (8195)
HPV39, 45, 52, 56, 68a 100 MID1 HPV39 (49), HPV45 (566),
HPV52 (178), HPV56 (41),
HPV68a (6327)
HPV35, 59, 66, 68b 10 MID2 HPV35 (36), HPV59 (5782),
HPV66 (949), HPV68b (4590)
HPV35, 59, 66, 68b 100 MID3 HPV35 (72), HPV59 (3145),
HPV66 (125), HPV68b (1292)
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(e.g. HPV51), although we cannot completely exclude the
presence of low level infection by some HPV types not
detected by 454 pyrosequencing. Finally, the 454 pyrose-
quencing method allowed the detection of HPV types that
cannot be identiﬁed by SPF10-LiPA (e.g. HPV61, HPV62
and HPV67).
Discussion
In this study, we developed a new method for HPV genotyping
based on 454 pyrosequencing of HPV L1 amplicons generated
with a new modiﬁed set of PGMY primers. This method was
sensitive, speciﬁc, quantitative, and precise in both single and
multiple infections. It could identify a wide range of HPV types
and might potentially discover new HPV types.
The NGS method could correctly identify all high-risk
HPV types, including HPV68a, which is not ampliﬁed by
PGMY primers. Targeting of HPV68a was achieved by the
addition of a new speciﬁc primer pair to the multiplex PGMY
primer set.
By testing different mixtures of HPV16- and HPV18-
positive cell lines, the 454 pyrosequencing method was
demonstrated to reproducibly quantify the proportion of
each HPV type in multiple infections, with a relatively high
dynamic range. However, some HPV types, such as HPV31,
HPV33, HPV51 and HPV56, appeared to be less efﬁciently
ampliﬁed, leading to an underestimation of their amount.
Nonetheless, the 454 pyrosequencing method could cor-
rectly detect all HPV types of the WHO proﬁciency panel at
the low 50 GE/5 lL level. In addition, a wide number of
different HPV types could be detected in samples with
multiple infections.
1
10
100
1000
10 000
100 000
(a)
(b)
1000:1 500:1 100:1 10:1 1:1 1:5
Proportion of HPV16 to HPV18 GE
R
ea
ds
 (n
o.
)
HPV16 (MID1)
HPV16 (MID2)
HPV18 (MID1)
HPV18 (MID2)
0
20
40
60
80
100
0 20 40 60 80 100
Proportion of HPV18 to HPV16 GE (%)
R
ea
ds
 (%
) HPV16 (MID1)
HPV16 (MID2)
HPV18 (MID1)
HPV18 (MID2)
FIG. 1. Results of 454 pyrosequencing analysis of pools of DNA
puriﬁed from CaSki (HPV16-positive) and HeLa (HPV18-positive) cells.
The analysis was performed in duplicate pool samples with PCR
primers containing either the multiplex identiﬁed MID1 or MID2. Pools
contained different proportions of DNA puriﬁed from cell lines (and
corresponding HPV genome equivalents, GE) ranging from 0.1% (i.e.
1000:1 HPV16 to HPV18) to 80% (i.e. 5:1) HPV16 GE of the total
amount of HPV16 and HPV18 GE in samples. Results are represented
as absolute number (a) and percentage (b) of reads of HPV18 and
HPV16 obtained in samples ampliﬁed in duplicate with MID1 and MID2
barcoded primers.
TABLE 3. Results of HPV genotyping of pools of HPV-
positive genital swab specimens by using a modiﬁed PGMY
primer mix and 454 pyrosequencing
HPV types
(SPF-10 LiPA)
Primer
MID
454 PGMY results
(No. reads)
HPV6, 16, 31a, 51,
52, 56
MID3 HPV6 (6557), HPV16 (203), HPV51 (18),
HPV56 (22), HPV58 (21), HPV61 (92),
HPV73 (38)
HPV6, 31, 56, (52)a,b MID3 HPV6 (11451), HPV31 (52), HPV42 (38),
HPV56 (33), HPV83 (32)
HPV16, 18, 52, 66a,
(51)a,b
MID3 HPV16 (11894), HPV18 (1316), HPV66 (41),
HPV55 (25), HPV89 (37), HPV11 (25)
HPV16, 44, 53, 66 MID3 HPV16 (4357), HPV53 (251), HPV66 (14107),
HPV44 (64)
HPV11, 16, 52a, 58 MID3 HPV11 (44), HPV16 (8003), HPV58 (29)
HPV11, 52, 59, 66 MID3 HPV11 (23), HPV52 (30), HPV59 (9276),
HPV66 (47)
HPV6, 11, 16, 44, 52 MID4 HPV6 (12805), HPV11 (19160),
HPV16 (218), HPV35 (10), HPV39 (11),
HPV44 (298), HPV52 (345), HPV54 (11),
HPV58 (29), HPV61 (176), HPV62 (21),
HPV83 (33)
HPV16, 44, 51, 52 MID5 HPV16 (9076), HPV44 (69), HPV51 (54),
HPV52 (255), HPV61 (105)
HPV16, 52, 58, 70 MID7 HPV16 (1453), HPV42 (21), HPV52 (2506),
HPV53 (27), HPV58 (1074), HPV61 (44),
HPV66 (48), HPV70 (16063), HPV89 (32)
HPV6, 11, 16, 31a,
44, 51, 53, 66
MID8 HPV6 (7950), HPV11 (870), HPV16 (1402),
HPV44 (124), HPV45 (335), HPV51 (212),
HPV53 (117), HPV66 (5188)
HPV types marked with a were detected by SPF10-LiPA only, while HPV types in
bold were detected by 454 only.
bThe presence of HPV types within brackets is deﬁned as possible by SPF10-LiPA.
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The method was useful for the analysis of samples with
discordant results obtained by two hybridization based-meth-
ods (i.e. the HC2 and the SPF10-LiPA assay), for which
problems of cross-hybridization and low-sensitivity for some
HPV types, respectively, have been reported [6,7,14–16].
Indeed, methods based on sequencing are expected to be
more speciﬁc than hybridization-based methods and are
considered the reference standard for genotyping. Our
method, based on sequencing of a 450-bp long fragment of
the L1 gene, allows us to achieve a very good speciﬁcity of
genotyping and, potentially, could lead to the discovery of a
new HPV types, for which a long sequence might provide
sufﬁcient information for phylogenetic analysis [17,18]. This
feature represents an advantage over methods based on the
analysis of very short sequences, such as the commercially
available HPV sign Genotyping test (Qiagen), which is based
on broad-spectrum ampliﬁcation of a variable region of HPV
L1 and pyrosequencing of short reads from the amplicons on
the Pyromark Q24 system (Qiagen). In addition, the HPV sign
Genotyping test was demonstrated to have a low sensitivity
for some HPV types and for the discrimination of HPV types in
multiple infections, but, on the other hand, being based on
sequencing of short amplicons, the assay was shown to be
suitable for testing archival formalin-ﬁxed parafﬁn-embedded
biopsies [19].
Costs and turnaround time are major problems with
diagnostic methods based on NGS technologies, as already
discussed in our previous proof of principle study [10]. Full
automation and standardization of protocols for library
preparation and sequencing are required for the implementa-
tion of this technology in routine diagnostics. Possible
applications of this genotyping method might include: (i)
second line testing in patients with HPV-related lesions for risk
stratiﬁcation, (ii) accurate analysis of HPV types in HPV-related
cancers, (iii) epidemiological monitoring of mucosal HPV type
distribution, (iv) detection of uncommon or novel HPV types;
and (v) any other application that requires accurate HPV typing
and estimation of the relative load in multiple infections.
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